Innocan Pharma to Present Innovative Cannabidiol Research at PAINWeek 2025 in Las Vegas

Innocan's Groundbreaking Presentation at PAINWeek 2025

Innocan Pharma Corporation, a leading entity in the pharmaceutical and biotechnology sectors, is set to make waves at the upcoming PAINWeek 2025 conference in Las Vegas, Nevada. From September 2 to 5, this premier event will attract a multitude of professionals dedicated to pain management, making it an ideal opportunity for Innocan to present its latest research findings.

One of the highlights will be a scientific poster titled "Is Long-Acting Synthetic Cannabidiol a Solution to Chronic Pain?" This presentation, scheduled for September 4, will delve deep into the company’s ongoing development of its innovative injectable liposomal product, LPT-CBD. This new formulation aims to provide a sustained release of synthetic cannabidiol (CBD), which is gaining recognition as a non-opioid alternative for pain management.

The poster will feature pivotal data on LPT-CBD's pharmacokinetics and efficacy. A recent narrative review supports its potential, asserting that synthetic cannabidiol, delivered through extended-release formulations, may serve as a well-tolerated analgesic option. The review, entitled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review", sheds light on the pivotal role synthetic CBD can play in addressing chronic pain, especially amid the urgent need to combat opioid dependency.

Innocan's LPT-CBD has shown promising results in preclinical studies, demonstrating the ability to maintain stable plasma CBD levels for up to four weeks and provide extended pain relief. This innovation is a significant advancement over traditional opioid medications, which present risks of dependency and other side effects. Through its controlled-release mechanism, LPT-CBD aims to ensure consistent therapeutic levels of CBD, distinguishing it from over-the-counter CBD products that often lack regulation and reliability.

The company's strategy focuses on tapping into the endocannabinoid system, a validated mechanism for modulating pain. By innovating in this space, Innocan believes LPT-CBD can represent a transformative approach in managing chronic pain without the risks associated with opioids. The current opioid crisis necessitates the exploration of non-opioid alternatives, and LPT-CBD may very well be a solution.

Iris Bincovich, CEO of Innocan, expressed immense pride in the opportunity to present at PAINWeek. "We are honored to be among the leading voices in the field presenting our findings this year. This recognition reaffirms our commitment to advancing evidence-based strategies for pain management while contributing valuable insights to the domain of pain care research," she stated.

The PAINWeek conference serves as a vital platform, gathering clinicians, researchers, and educators dedicated to pain management. Innocan’s participation underscores its dedication to addressing the complexities of chronic pain management and reflects its focus on safe, effective alternatives to traditional pain relief methods.

Innocan Pharma is not only making strides in pharmaceuticals but also in wellness. The company engages in the development of a diverse array of self-care and beauty products aimed at fostering a healthier lifestyle, signaling its multifaceted approach to healthcare.

For those attending PAINWeek 2025, Innocan's poster session promises to be a highlight. Interested parties are encouraged to connect with the company representatives to discuss potential collaborations and learn more about the innovative applications of LPT-CBD in pain management.

With repercussions of the opioid crisis still relevant today, the introduction of alternative therapies is crucial. LPT-CBD holds significant promise, and Innocan’s innovative efforts could inevitably lead to a paradigm shift in how chronic pain is approached in both clinical and everyday settings.